Ratio Therapeutics raised $70 million to support radiopharmaceutical trials, according to the company’s Series C update. The financing includes participation from existing investors Duquesne Family Office and Bristol Myers Squibb, alongside new backers. The round signals investor support for scaling and de-risking radiopharma programs through clinical execution, where trial design and production readiness often determine timelines for pivotal data.